Skip to main content
. Author manuscript; available in PMC: 2017 Jan 6.
Published in final edited form as: Lancet Neurol. 2015 Jun 3;14(8):855–866. doi: 10.1016/S1474-4422(15)00006-X

Table 3. Active clinical trials testing new emergent drugs and/or targets for PD treatment.

PD: Parkinson’s disease; α-syn: α-synuclein; MSA: multiple system atrophy: UMSARS-ME: motor examination (ME) of the Unified MSA Rating Scale

ClinicalTrials.gov
identifiers		 Title Primary outcome measures
NCT01885494 AFF008E: Observational Phase 1b Follow-up Extension Study
for Patients With PD After Immunization With AFFITOPE®
PD01A 		Tolerability and Safety
NCT02046434 Phenylbutyrate As a Treatment for Abnormal Accumulation of
Brain Protein in PD		 Levels of α-syn in blood plasma
NCT02095171 Single Ascending Dose Study of PRX002 in Healthy Subjects Safety, tolerability and pharmacokinetics
NCT02157714 Multiple Ascending Dose Study of PRX002 in Patients With PD Safety, tolerability and pharmacokinetics
NCT02008721 Progression Rate of MSA Under EGCG Supplementation as
Anti-Aggregation-Approach		 UMSARS – ME